Hopes for HIV vaccine buoyed by start of second big trial
.Scientists announced the launch of another large HIV vaccine efficacy study on Thursday, fueling hopes for a protective shot against the virus that causes AIDS, despite past disappointments.
The start of the new trial involving 2,600 women in southern Africa means that for the first time in more than a decade there are now two big HIV vaccine clinical trials taking place at the same time.
The new study is testing a two-vaccine combination developed by Johnson & Johnson with the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. The first vaccine, also backed by NIH, began a trial last November.
Both studies aim to build on the modest success of a previous trial in Thailand in 2009, when an earlier vaccine showed a 31-percent reduction in infections.